I thought bisantrene concentration and FTO inhibition, just like with cardioprotection, is not linearly related and is dose-dependent. One big thing with bisantrene is synergy synergy synergy. It makes other drugs work better, at no added cost to the patient. So in Sheba 2, it is possible the response rates are not related to FTO etc but due to the other 2 combo drugs. We won't know until more data is released, but it's a win-win. Either it's FTO, or it's still bisantrene, but by amplifying the impact of the other drugs. Just my thoughts
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-107
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
-0.040(2.23%) |
Mkt cap ! $297.9M | |||
| Open | High | Low | Value | Volume |
| $1.79 | $1.79 | $1.72 | $146.2K | 83.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2901 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 994 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.74 |
Change
-0.040 ( 1.51 %) |
||||
| Open | High | Low | Volume | ||
| $1.76 | $1.77 | $1.72 | 23546 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| RAC (ASX) Chart |
